The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)
VaccinePublished 1 December 2002
Jan Bonhoeffer, Katrin Kohl, Robert HC Chen, Philippe Duclos, Harald Heijbel, Ulrich Heininger
Citations159
SJR quartileQ1
SJR score1.25
SNIP0.97
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
Diversity in safety methods leads to considerable loss of scientific information. We have built the necessary international network of currently about 300 participants from patient care, public health, scientific, pharmaceutical, regulatory and professional organizations to develop and assess standardized AEFI case definitions and guidelines. Evaluation studies, global implementation, ongoing definition development and a continuously growing network will be essential for the success of the collaboration.
Keywords
Immunology and MicrobiologySocial SciencesMedicine
Drug SafetyThe Medical Dictionary for Regulatory Activities (MedDRA)
1,379 Citations1999Elliot G. Brown, Louise Wood +1 more
It is anticipated that using MedDRA will improve the quality of data captured on databases, support effective analysis by providing clinically relevant groupings of terms and facilitate electronic communication of data, although as a new tool, users will need to invest time in gaining expertise in its use.
New England Journal of MedicineIntussusception among Infants Given an Oral Rotavirus Vaccine
976 Citations2001Trudy V. Murphy, Paul Gargiullo +11 more
The strong association between vaccination with RRV-TV and intussusception among otherwise healthy infants supports the existence of a causal relation.
New England Journal of MedicineA Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine
729 Citations1996Lennart Gustafsson, Hans O. Hallander +3 more
The five-component acellular pertussis vaccine evaluated can be recommended for general use, since it has a favorable safety profile and confers sustained protection against pertussi.
New England Journal of MedicineA Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
710 Citations1996Donatella Greco, Stefania Salmaso +10 more
The two acellular DTP vaccines studied were safe, immunogenic, and efficacious against pertussis, whereas the efficacy of the whole-cell DTP vaccine was unexpectedly low.
PEDIATRICSNature and Rates of Adverse Reactions Associated with DTP and DT Immunizations in Infants and Children
538 Citations1981Christopher L. Cody, Larry J. Baraff +3 more
In 784 DT and 15,752 DTP immunizations given to children 0 to 6 years of age who were prospectively studied for reactions occurring within 48 hours following immunization, minor reactions were significantly more frequent following DTP vaccine.
VaccineThe vaccine adverse event reporting system (VAERS)
485 Citations1994Robert T. Chen, S RASTOGI +5 more
The LancetRandomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
331 Citations1997P Olin, Finn Rasmussen +3 more
From the first dose in the 3 months, 5 months, 12 months schedule the whole-cell vaccine was significantly more protective than the three-component vaccine against typical pertussis, and the serological response of the acellular vaccines in the 2 months, 4 months, 6 months schedule were similar to those previously reported.
VaccineA randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
268 Citations1997François Simondon, Marie‐Pierre Préziosi +11 more
Although vaccination with DTaP provided a lower degree of protection than the highly effective DTwP, this difference was less prominent before 18 months of age, the customary age for a fourth dose.
The Pediatric Infectious Disease JournalPopulation-based study of rotavirus vaccination and intussusception
225 Citations2001Piotr Kramarz, Eric K. France +10 more
A retrospective cohort study in ten managed care organizations found that RRV-TV is associated with an increased risk of intussusception, and the risk is greatest 3 to 7 days after the first vaccination dose.
VaccineVaccine risks: real, perceived and unknown
170 Citations1999Robert T. Chen
Modernization of the vaccine safety infrastructure commensurate with the current investment in vaccine development will be needed if the full promise of new vaccines made possible by the biotechnology revolution are likely to be fulfilled.
PEDIATRICSIntussusception Among Recipients of Rotavirus Vaccine: Reports to the Vaccine Adverse Event Reporting System
114 Citations2001Lynn R. Zanardi, Penina Haber +4 more
Using a passive surveillance system for vaccine adverse events, at least a fourfold increase over the expected number of intussusception cases occurring within 1 week of receipt of rotavirus vaccine is observed.
The Pediatric Infectious Disease JournalEfficacy of a two-component acellular pertussis vaccine in infants
101 Citations1997Johannes G. Liese, Carlton Meschievitz +9 more
The Pediatric Infectious Disease JournalReactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children
80 Citations1999Vytautas Usonis, V. Bakasénas +3 more
When administered as primary vaccination in children in the second year of life, the new SB MMR vaccine has been shown to be superior to a comparator vaccine in terms of local reactogenicity, with equivalent immunogenicity.
PEDIATRICSSevere Reactions Associated With Diphtheria-Tetanus-Pertussis Vaccine: Detailed Study of Children With Seizures, Hypotonic-Hyporesponsive Episodes, High Fevers, and Persistent Crying
78 Citations1993Dean A. Blumberg, Patricia Chatfield +4 more
Seizures associated with DTP vaccine have similar clinical characteristics as febrile seizures, and persistent crying is initiated by painful local reactions.
The Journal of PediatricsClinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants
73 Citations1996Heinz J. Schmitt, Anne Schuind +10 more
In a large cohort of 22,505 infants vaccinated, SmithKline Beecham Biologicals' tricomponent DTaP vaccine was shown to be safe, well-tolerated, and immunogenic for all component antigens.
VaccineSafety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age
71 Citations1998Elaine L. Mills, Ronald Gold +9 more
CPDT-IPV//PRP-T was safe and immunogenic in infants and antibody results were similar to those observed in a Swedish field trial that demonstrated CPDT to be 85% effective in preventing clinical pertussis.
Archives of Disease in ChildhoodRe-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service
69 Citations2000Michael Gold
Re-vaccination of children who have a past history of an AEFI appears safe, and a special immunisation service should be part of a comprehensive immunisation programme.
VaccineAdverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study
67 Citations2001Robert M. Jacobson, Adedunni Adegbenro +2 more
It is contention that the possibility of a rare but serious vaccine adverse effect is difficult to detect in prelicensure testing, and that only after hundreds of thousands of doses of vaccines are distributed will such rare events appear often enough to permit detection.
PEDIATRICSReport of a US Public Health Service Workshop on Hypotonic–Hyporesponsive Episode (HHE) After Pertussis Immunization
55 Citations1998M. Miles Braun, Gina J. Terracciano +7 more
The US Food and Drug Administration sponsored a workshop on HHE and assessed the possible contribution VAERS-based studies could make to answering this question and found substantial methodologic problems; however, ongoing studies in Sweden and The Netherlands have the potential to provide useful information on this question.
VaccineComparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9–11, 12–14 or 15–17 months of age☆☆Results of this study were presented at the annual meetings of the German Society for Paediatrics and Adolescent Medicine, September 1997, Vienna (Austria) and the German Society for Paediatric Infectious Diseases, November 1997, Berlin (Germany).
53 Citations2000J. Klinge, S. Lugauer +3 more
Immunisation against MMR is safe and effective even when administered before the currently recommended age of 12 months, and local side reactions were mild, infrequent and independent of age.
BMJRate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study
48 Citations1998Patricia E. Vermeer-de Bondt, Jerry Labadie +1 more
Although the rate of recurrent collapse after whole cell pertussis vaccine has not been studied, for over 30 years repeat doses of vaccine have been contraindicated in children who experience a collapse reaction.
Pharmacoepidemiology and Drug SafetySafety considerations for new vaccine development
42 Citations2001Susan S. Ellenberg
Information would increase confidence in the safety of vaccines, be a valuable resource for assessing spontaneous reports of adverse events after licensure, and would reduce the risk of licensing a new vaccine that had the potential to cause severe injury to a small proportion of vaccinees.
Journal of Paediatrics and Child HealthVaccination of children following a previous hypotonic–hyporesponsive episode
38 Citations1999Helen Goodwin, Margot Nash +3 more
Hypotonic–hyporesponsive episodes (HHE) were once considered a contraindication to pertussis vaccination but are now considered a non-contraildication.
JAMAAntibody Response to Measles-Mumps-Rubella Vaccine of Children With Mild Illness at the Time of Vaccination
36 Citations1996Gail E. King
VaccineReactogenicity and immunogenicity of a new combined Measles–Mumps–Rubella vaccine: results of a multicentre trial
26 Citations2000Pietro Crovari, Giovanni Gabutti +5 more
The trial demonstrates 'Priorix' is well tolerated and highly immunogenic and the results showed no appreciable decline in titres with either vaccine.
The Pediatric Infectious Disease JournalSafety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R®II, VARIVAX® and TETRAMUNE® in healthy children vs. concomitant injections of M-M-R®II and TETRAMUNE® followed six weeks later by VARIVAX®
23 Citations1998Henry R. Shinefield, Steven Black +8 more
It is expected that the concomitant administration of VARivAX with M-M-R II and TETRAMUNE has clinical effectiveness similar to that with VARIVAX 6 weeks after the administration of these other two vaccines.
PubMedMinor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
22 Citations1997Michael A. Überall, K Stehr +5 more
Local reactions (erythema and induration) and systemic events (fever, fretfulness, drowsiness and anorexia) were more common after each dose of DTP vaccine than after the DTaP and DT vaccine doses.
PubMedDoes whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
7 Citations1991Arthi Ramkissoon, H. M. Coovadia +2 more
Significant pertussis antibody levels were found in maternal and cord sera with levels in the latter frequently being higher, and in contrast with the positive increases in these antibodies found in other series of whole-cell vaccination.
PubMedMonitoring and safety assessment in Phase I to III clinical trials.
3 Citations1998Reinhard Fescharek, Uwe Nicolay +1 more
To achieve a balanced risk-to-benefit evaluation the input of a central safety department is recommended from planning of a clinical development to post-marketing phase, and an integrated safety plan with standardized procedures improves the likelihood of detecting a realistic AE-profile, prior to marketing a vaccine.
